|
Name |
Ophiobolin S
|
Molecular Formula | C26H40O5 | |
IUPAC Name* |
(1R,3S,4R,7R,8E,11S,12R)-4-hydroxy-12-[(2S)-6-hydroxy-5-methoxy-6-methylhept-3-en-2-yl]-1,4-dimethyl-6-oxotricyclo[9.3.0.03,7]tetradec-8-ene-8-carbaldehyde
|
|
SMILES |
C[C@@H](C=CC(C(C)(C)O)OC)[C@H]1CC[C@]2([C@H]1C/C=C(\[C@H]3[C@H](C2)[C@](CC3=O)(C)O)/C=O)C
|
|
InChI |
InChI=1S/C26H40O5/c1-16(7-10-22(31-6)24(2,3)29)18-11-12-25(4)13-20-23(21(28)14-26(20,5)30)17(15-27)8-9-19(18)25/h7-8,10,15-16,18-20,22-23,29-30H,9,11-14H2,1-6H3/b10-7?,17-8-/t16-,18+,19-,20-,22?,23-,25+,26+/m0/s1
|
|
InChIKey |
GIBPHPHOBXYRHB-PZFMCOCGSA-N
|
|
Synonyms |
Ophiobolin S
|
|
CAS | NA | |
PubChem CID | 139586271 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 432.6 | ALogp: | 2.9 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.8 | Aromatic Rings: | 3 |
Heavy Atoms: | 31 | QED Weighted: | 0.476 |
Caco-2 Permeability: | -4.611 | MDCK Permeability: | 0.00001930 |
Pgp-inhibitor: | 0.992 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.225 | 20% Bioavailability (F20%): | 0.053 |
30% Bioavailability (F30%): | 0.196 |
Blood-Brain-Barrier Penetration (BBB): | 0.061 | Plasma Protein Binding (PPB): | 92.62% |
Volume Distribution (VD): | 1.241 | Fu: | 4.76% |
CYP1A2-inhibitor: | 0.022 | CYP1A2-substrate: | 0.323 |
CYP2C19-inhibitor: | 0.038 | CYP2C19-substrate: | 0.773 |
CYP2C9-inhibitor: | 0.108 | CYP2C9-substrate: | 0.059 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.08 |
CYP3A4-inhibitor: | 0.687 | CYP3A4-substrate: | 0.547 |
Clearance (CL): | 2.861 | Half-life (T1/2): | 0.236 |
hERG Blockers: | 0.045 | Human Hepatotoxicity (H-HT): | 0.024 |
Drug-inuced Liver Injury (DILI): | 0.197 | AMES Toxicity: | 0.031 |
Rat Oral Acute Toxicity: | 0.037 | Maximum Recommended Daily Dose: | 0.891 |
Skin Sensitization: | 0.312 | Carcinogencity: | 0.081 |
Eye Corrosion: | 0.009 | Eye Irritation: | 0.038 |
Respiratory Toxicity: | 0.962 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003777 | 0.708 | D0N1TP | 0.289 | ||||
ENC003783 | 0.691 | D0G8OC | 0.244 | ||||
ENC002000 | 0.691 | D0Q6NZ | 0.242 | ||||
ENC002981 | 0.594 | D0G5CF | 0.241 | ||||
ENC003251 | 0.467 | D0W5LS | 0.241 | ||||
ENC002983 | 0.459 | D0P0HT | 0.240 | ||||
ENC001559 | 0.446 | D0I2SD | 0.238 | ||||
ENC005047 | 0.446 | D08IWD | 0.236 | ||||
ENC002982 | 0.404 | D0K0EK | 0.235 | ||||
ENC005803 | 0.389 | D0L2LS | 0.233 |